ARQT vs. OCUL, LQDA, BCYC, CNTA, OPK, TYRA, ETNB, IMNM, ABVX, and SPRY
Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Ocular Therapeutix (OCUL), Liquidia (LQDA), Bicycle Therapeutics (BCYC), Centessa Pharmaceuticals (CNTA), OPKO Health (OPK), Tyra Biosciences (TYRA), 89bio (ETNB), Immunome (IMNM), ABIVAX Société Anonyme (ABVX), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical preparations" industry.
Arcutis Biotherapeutics (NASDAQ:ARQT) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
Ocular Therapeutix has a net margin of -192.61% compared to Arcutis Biotherapeutics' net margin of -204.35%. Ocular Therapeutix's return on equity of -76.64% beat Arcutis Biotherapeutics' return on equity.
59.2% of Ocular Therapeutix shares are held by institutional investors. 20.7% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 5.5% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Ocular Therapeutix received 372 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 69.72% of users gave Ocular Therapeutix an outperform vote while only 62.07% of users gave Arcutis Biotherapeutics an outperform vote.
Ocular Therapeutix has lower revenue, but higher earnings than Arcutis Biotherapeutics. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Arcutis Biotherapeutics had 16 more articles in the media than Ocular Therapeutix. MarketBeat recorded 22 mentions for Arcutis Biotherapeutics and 6 mentions for Ocular Therapeutix. Arcutis Biotherapeutics' average media sentiment score of 0.70 beat Ocular Therapeutix's score of -0.08 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.
Arcutis Biotherapeutics currently has a consensus target price of $27.00, indicating a potential upside of 193.48%. Ocular Therapeutix has a consensus target price of $15.17, indicating a potential upside of 145.81%. Given Arcutis Biotherapeutics' higher probable upside, equities research analysts clearly believe Arcutis Biotherapeutics is more favorable than Ocular Therapeutix.
Arcutis Biotherapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.
Summary
Ocular Therapeutix beats Arcutis Biotherapeutics on 10 of the 18 factors compared between the two stocks.
Get Arcutis Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcutis Biotherapeutics Competitors List
Related Companies and Tools
